Pakistani pharmaceutical company signs agreement with Gilead to produce and expand supply of Remdesivir drug
Pakistan will soon start manufacturing the COVID-19 treatment drug under license from a pharmaceutical company in the United States, Special Assistant to Prime Minister on National Health Services Dr Zafar Mirza announced on Friday.
Pakistan is one of the five countries that the US company Gilead has signed a licensing agreement with for manufacturing the drug and distribution in 127 countries.
The company would receive a technology transfer of the Gilead manufacturing process “to enable them to scale up production more quickly.”
The Drug Regulatory Authority of Pakistan (DRAP) has been directed to conduct a fast-track registration of the anti-viral medicine which will be administered to patients in the form of an injection.
Osman Khalid, CEO of Ferozsons Laboratories CEO, says that his company would make the drug available for the lowest possible price.